Table 3.
Number of oocytes and total gonadotrophin dose for hMG versus r-hFSH
| Studied endpoint for hMG versus r-hFSH | MD | 95% CI | p value | SDM | 95% CI | P value |
|---|---|---|---|---|---|---|
| Number of oocytes | ||||||
| - Main analysis | -1.54 | -2.53, -0.56 | < 0.0001 | -0.23 | -0.36, -0.10 | < 0.0001 |
| - Sub-group 1 | -1.68 | -2.69, -0.68 | < 0.0001 | -0.25 | -0.38, -0.12 | < 0.0001 |
| - Sub-group 2 | -1.57 | -2.65, -0.49 | < 0.001 | -0.24 | -0.38, -0.11 | < 0.0001 |
| - Main analysis (fixed model) | -1.74 | -2.12, -1.35 | < 0.0001 | -0.26 | -0.32, -0.19 | < 0.0001 |
| Number of oocytes adjusted for baseline | -2.10 | -2.83, -1.36 | < 0.001 | -0.35 | -0.47, -0.22 | < 0.0001 |
| Dosage (IU) | 235.46 | 16.62, 454.30 | 0.03 | 0.33 | 0.08, 0.58 | 0.01 |
hMG = human menopausal gonadotrophins; r-hFSH = recombinant human follicle-stimulating hormone; MD = mean difference; SDM = standardized mean difference